Fresenius Kabi Aktiengesellschaft, commonly referred to as Fresenius Kabi, is a global healthcare company headquartered in Bad Homburg, Germany. Founded in 1999, the company has established itself as a leader in the pharmaceutical and medical technology sectors, focusing on lifesaving medicines and technologies. Fresenius Kabi operates in over 100 countries, with significant presence in Europe, North America, and Asia. The company’s core offerings include intravenous (IV) drugs, infusion therapies, and clinical nutrition products, all designed to enhance patient care. Notably, Fresenius Kabi is recognised for its commitment to quality and innovation, which has solidified its position in the market. With a strong emphasis on sustainability and patient safety, Fresenius Kabi continues to achieve notable milestones, contributing significantly to the global healthcare landscape.
How does Fresenius Kabi Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius Kabi Aktiengesellschaft's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fresenius Kabi Aktiengesellschaft, headquartered in Germany (DE), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Fresenius SE & Co. KGaA, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Fresenius Kabi. The absence of specific emissions data and reduction initiatives suggests that the company may be in the early stages of developing its climate strategy or reporting framework. Fresenius Kabi's climate commitments may be informed by the broader sustainability initiatives of its parent company, Fresenius SE & Co. KGaA, which has been active in addressing climate change and may have cascading targets or performance metrics that impact Fresenius Kabi's operations. However, without specific data or targets from Fresenius Kabi itself, it is challenging to provide a detailed overview of its carbon emissions and climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 
Fresenius Kabi Aktiengesellschaft's Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 44% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fresenius Kabi Aktiengesellschaft has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.